ERBB2 and carcinoma: HER2 amplifications drive oncogenesis in a significant proportion of aggressive epithelial cancers (carcinomas) including in particular subsets of breast cancer [16] and salivary gland cancer [17] where it is detectable in 15 – 30% of cases.